Abstract
TPP reduces adult height. During its first year of administration, the LH RH agonist D-Trp6 (Decapeptyl®) decreased growth velocity and bone maturation, but its long term effects have not been analyzed. Fourteen girls had onset of idiopathic TPP at 6.3±1.2 yrs: their growth rate was 9.7±3.5 cm/yr and bone age 8.9±1.9 yr. The girls received 1 injection/mo of a depot preparation of the agonist during 4.8±1.2 yrs. Growth rate stabilized at 4±1.2 cm per yr (p<0.005 vs pretreatment) and bone age increased by only 0.85±0.15 yr/yr. At the end of treatment, height was 151.5±6.2 cm and bone age 12.3±0.6 yrs. Growth rate remained at 4.4±2 cm/yr during the following 6-34 months. Therefore, 7±1.3 yrs after the onset of treatment with the LH-RH agonist, height was 157±8 cm and bone age 13.2±1.1 yrs, producing a final height prognosis of 162±5 cm. We conclude that treatment of true precocious puberty with D-Trp6-LH-RH increases final height prognosis.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zeller, J., Bougneres, P. & Chaussain, J. LONG TERM CONTROL OF GROWTH RATE AND BONE MATURATION BY LH RH AGONIST IN GIRLS WITH TRUE PRECOCIOUS PUBERTY (TPP). Pediatr Res 33 (Suppl 5), S38 (1993). https://doi.org/10.1203/00006450-199305001-00212
Issue Date:
DOI: https://doi.org/10.1203/00006450-199305001-00212